

Biagio Pucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9337003/publications.pdf>

Version: 2024-02-01

29
papers

1,028
citations

394421

19
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

2356
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 184-200.	1.6	83
2	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 317.	8.6	82
3	Biotin-targeted Pluronic [®] P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells. <i>International Journal of Pharmaceutics</i> , 2016, 511, 127-139.	5.2	71
4	Structural analysis of the <i>Sulfolobus solfataricus</i> MCM protein N-terminal domain. <i>Nucleic Acids Research</i> , 2008, 36, 3235-3243.	14.5	65
5	Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. <i>Cell Death and Disease</i> , 2016, 7, e2120-e2120.	6.3	65
6	Purification and Characterization of a Novel Recombinant Highly Enantioselective Short-Chain NAD(H)-Dependent Alcohol Dehydrogenase from <i>Thermus thermophilus</i> . <i>Applied and Environmental Microbiology</i> , 2008, 74, 3949-3958.	3.1	60
7	The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. <i>Cell Death and Disease</i> , 2016, 7, e2108-e2108.	6.3	58
8	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e641-e641.	6.3	57
9	Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. <i>Oncotarget</i> , 2015, 6, 25074-25092.	1.8	53
10	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. <i>Cell Death and Disease</i> , 2013, 4, e878-e878.	6.3	50
11	Biochemical Characterization of a CDC6-like Protein from the Crenarchaeon <i>Sulfolobus solfataricus</i> . <i>Journal of Biological Chemistry</i> , 2003, 278, 46424-46431.	3.4	43
12	Modular Organization of the <i>Sulfolobus solfataricus</i> Mini-chromosome Maintenance Protein. <i>Journal of Biological Chemistry</i> , 2007, 282, 12574-12582.	3.4	30
13	Evaluation of Selenite Effects on Selenoproteins and Cytokinome in Human Hepatoma Cell Lines. <i>Molecules</i> , 2013, 18, 2549-2562.	3.8	30
14	Amino Acids of the <i>Sulfolobus solfataricus</i> Mini-chromosome Maintenance-like DNA Helicase Involved in DNA Binding/Remodeling. <i>Journal of Biological Chemistry</i> , 2004, 279, 49222-49228.	3.4	29
15	New pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. <i>FASEB Journal</i> , 2010, 24, 2881-2892.	0.5	26
16	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213.	8.6	26
17	Characterization of serum immunoglobulin M of the Antarctic teleost <i>Trematomus bernacchii</i> . <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2003, 135, 349-357.	1.6	24
18	Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in HepG2 cancer cells. <i>Proteomics</i> , 2011, 11, 3725-3742.	2.2	21

#	ARTICLE	IF	CITATIONS
19	Biochemical characterization of a recombinant short-chain NAD(H)-dependent dehydrogenase/reductase from <i>Sulfolobus acidocaldarius</i> . <i>Extremophiles</i> , 2010, 14, 193-204.	2.3	20
20	Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. <i>Oncotarget</i> , 2015, 6, 5324-5341.	1.8	20
21	A CDC6-like Factor from the Archaea <i>Sulfolobus solfataricus</i> Promotes Binding of the Mini-chromosome Maintenance Complex to DNA. <i>Journal of Biological Chemistry</i> , 2004, 279, 43008-43012.	3.4	19
22	Modular organization of a Cdc6-like protein from the crenarchaeon <i>Sulfolobus solfataricus</i> . <i>Biochemical Journal</i> , 2004, 381, 645-653.	3.7	17
23	Proteomic characterization of peroxisome proliferator-activated receptor ³ (PPAR ³) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. <i>Molecular Oncology</i> , 2016, 10, 1344-1362.	4.6	16
24	A novel DNA helicase with strand-annealing activity from the crenarchaeon <i>Sulfolobus solfataricus</i> . <i>Biochemical Journal</i> , 2007, 408, 87-95.	3.7	15
25	Biochemical evidence of a physical interaction between <i>Sulfolobus solfataricus</i> B-family and Y-family DNA polymerases. <i>Extremophiles</i> , 2007, 11, 277-282.	2.3	15
26	Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small cell lung cancer cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 9077-9092.	4.1	11
27	Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. <i>Amino Acids</i> , 2017, 49, 517-528.	2.7	9
28	HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 1005-1023.	4.6	8
29	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. <i>Cancers</i> , 2022, 14, 695.	3.7	3